tiprankstipranks
I-Tech AB (SE:ITECH)
:ITECH
Sweden Market
Want to see SE:ITECH full AI Analyst Report?

I-Tech AB (ITECH) AI Stock Analysis

3 Followers

Top Page

SE:ITECH

I-Tech AB

(ITECH)

Select Model
Select Model
Select Model
Outperform 79 (OpenAI - Gpt-5.6Sol)
Rating:79Outperform
Price Target:
kr85.00
▲(57.99% Upside)
Action:Reiterated
Date:08/22/26
The score is driven primarily by strong financial quality—debt-free balance sheet, solid profitability, and strong cash conversion—supported by a clear uptrend in technicals. These positives are tempered by a less attractive valuation (P/E ~25.5 with a modest ~1.69% yield) and some historical volatility in revenue/gross margins.
Positive Factors
Profitable growth
Recent growth combined with strong profitability indicates effective commercialization and operating leverage. If sustained, this earnings base can support reinvestment and widen the company’s ability to scale Selektope adoption.
Negative Factors
Revenue and margin volatility
The weaker 2025 revenue and gross-margin profile shows that earnings may remain sensitive to customer mix, pricing and costs. Such variability can make future profitability less predictable even while the recent TTM performance remains strong.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitable growth
Recent growth combined with strong profitability indicates effective commercialization and operating leverage. If sustained, this earnings base can support reinvestment and widen the company’s ability to scale Selektope adoption.
Read all positive factors

I-Tech AB (ITECH) vs. iShares MSCI Sweden ETF (EWD)

I-Tech AB Business Overview & Revenue Model

Company Description
I-Tech AB, a biotechnology firm established in Mölndal, Sweden, in 2000, focuses on creating and commercializing products to prevent biofouling. Their flagship innovation is Selektope, a unique bio-repellent ingredient engineered for marine coatin...
How the Company Makes Money
I-Tech AB makes money primarily by commercializing Selektope® as an active ingredient for use in antifouling paint and coating formulations. Revenue is generated through sales of Selektope® to coating manufacturers and/or through licensing-type ar...

I-Tech AB Financial Statement Overview

Summary
Strong overall fundamentals supported by high profitability and solid growth (TTM revenue +16.5%), excellent balance-sheet strength (zero debt in 2025 and TTM; strong ROE ~19–25%), and strong cash generation (FCF nearly equal to net income; TTM FCF growth +43%). Main risks are variability in revenue and gross margin (2025 revenue slightly down vs 2024 and lower gross margin) and evidence of cyclicality (loss-making and negative cash flow in 2021).
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
86
Very Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue191.03M168.12M179.45M120.86M83.63M52.90M
Gross Profit49.79M47.43M95.22M63.54M45.13M27.48M
EBITDA68.31M49.74M54.31M30.34M18.06M1.60M
Net Income48.61M33.19M39.01M20.20M10.62M-2.65M
Balance Sheet
Total Assets223.52M193.73M173.11M152.44M125.41M115.12M
Cash, Cash Equivalents and Short-Term Investments165.40M148.16M100.16M83.26M52.75M35.01M
Total Debt0.000.007.79M0.002.25M4.29M
Total Liabilities30.59M19.35M15.73M16.20M9.37M10.19M
Stockholders Equity192.93M174.39M157.39M136.24M116.03M104.94M
Cash Flow
Free Cash Flow67.03M64.51M35.04M32.76M20.06M-2.43M
Operating Cash Flow68.56M64.60M35.17M35.14M20.13M-1.70M
Investing Cash Flow-1.53M-409.00K-408.00K-2.38M-822.00K-928.00K
Financing Cash Flow-14.28M-16.20M-17.86M-2.25M-1.56M-3.35M

I-Tech AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
kr926.23M19.313.31%2.13%22.09%
69
Neutral
kr27.10M8.98-17.14%88.76%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
54
Neutral
kr149.76M54.981.04%2.89%-14.23%84.80%
49
Neutral
kr427.28M-33.3054.37%52.22%
46
Neutral
kr436.92M-9.763.26%16.82%
43
Neutral
kr69.07M-1.36-166.81%-21.95%-28.77%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ITECH
I-Tech AB
78.20
-10.07
-11.40%
SE:POLYG
Polygiene AB
4.42
-4.34
-49.52%
SE:ORGC
OrganoClick AB
0.41
-1.43
-77.66%
SE:ENZY
Enzymatica AB
1.81
-0.59
-24.58%
SE:CLBIO
Corline Biomedical AB
16.40
3.45
26.64%
SE:PCAT
Photocat A/S
5.20
-2.80
-35.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2026